Navigation Links
Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
Date:8/29/2011

MISSISSAUGA, Ontario, Aug. 29, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") announced today that its Board of Directors has approved an increase of $300 million under its previously announced securities repurchase program (the "Securities Repurchase Program").  Under the Securities Repurchase Program, Valeant may now repurchase up to $1.8 billion of its convertible notes, senior notes, common shares and/or other notes or shares that may be issued prior to the completion of the program. As part of this Securities Repurchase Program, Valeant also recently announced that it had filed a Notice of Intention to make a normal course issuer bid to repurchase up to 1,000,000 of its common shares through the facilities of the Toronto Stock Exchange ("TSX").

The Securities Repurchase Program will terminate on November 7, 2011 or at such time as Valeant completes its purchases.  To date, the Company has purchased 14,969,599 of its common shares for aggregate consideration of $590.6 million and a total of $302.5 million principal amount of its 5.375% Convertible Notes for aggregate consideration of $806.3 million. The amount of securities to be purchased and the timing of purchases under the Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under the Company's financing agreements. The securities to be repurchased will be funded using Valeant's cash resources.

Valeant believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds. The Securities Repurchase Program may be modified, suspended or terminated at any time without prior notice.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) i
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. ... the United States , European Union ... EMA and MHLW, respectively) for eribulin, for the treatment ... have received prior chemotherapy for advanced or metastatic disease. ... data from a pivotal global Phase 3 clinical trial ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Oncobiologics announced today that it has signed two ... early-stage biotech company, and involves worldwide licensing for an ... based large pharmaceutical company to conduct research focused on ... The identity of the client firm was not disclosed ...
... Oct. 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. ... China-based advanced in-vitro diagnostic ("IVD") company, today announced that ... approved the Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma ... as a companion diagnostic test for the use of ...
Cached Medicine Technology:Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...
(Date:7/31/2015)... , ... August 01, 2015 , ... The Honor Society ... Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, ... participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel ...
(Date:7/31/2015)... ... 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening ... first provider of Exilis non-surgical fat reduction in New York. Due to its ... large International clientele. Many patients travel to New York to get their non-surgical ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... Than 33 Percent Traffic GrowthJERSEY CITY, N.J., March ... interactive marketing company that specializes in connecting health ... announced strong growth during 2008, along with significant ... site QualityHealth.com. The Company has used the down ...
... Exhibit , www.donaldverger.com PORTLAND, Maine, March 3 A ... a period of three days at the start of the ... compelled to turn his experience into something positive. , ... Verger for using his considerable talents to help the Innocence ...
... ANGELES, March 3 Dr. Brian S. Boxer Wachler, ... the Boxer Wachler Vision Institute in Beverly Hills, California, ... that uses vitamin applications to treat Keratoconus, an often ... patients. Dr. Boxer Wachler,s new treatment, C3-R(R) (corneal ...
... caused by faulty signalling in the brain, according to ... Psychiatry . In the biggest study of its kind, ... people with the condition have identified 49 genes that ... to controls. , Many of these genes are involved ...
... premier surgical and medical equipment supplier, now sells its DRE Integra AV-S ... be utilized as patients attempt to breathe spontaneously. , ... (Vocus) March ... of the Year by Business First of Louisville, continues expanding its ...
... scientists receive prestigious research fellowships worth US$1.5 million each , ... ... scientists have been awarded research grants from the National Research Foundation ... Singapore. These scientists hail from six nations including China, Estonia, ...
Cached Medicine News:Health News:Marketing Technology Solutions Announces Strong 2008 Growth and Web Site Enhancements for QualityHealth.com 2Health News:Victim of Mistaken Identity, Critically Acclaimed Photographer and Museum Founder to Hold Benefit for the Innocence Project 2Health News:Victim of Mistaken Identity, Critically Acclaimed Photographer and Museum Founder to Hold Benefit for the Innocence Project 3Health News:Victim of Mistaken Identity, Critically Acclaimed Photographer and Museum Founder to Hold Benefit for the Innocence Project 4Health News:New Vitamin Treatment Saves Patients (Including a U.S. Olympic Athlete) from Blinding Eye Disease Without Surgery 2Health News:New Vitamin Treatment Saves Patients (Including a U.S. Olympic Athlete) from Blinding Eye Disease Without Surgery 3Health News:Schizophrenia linked to signaling problems in new brain study 2Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 2Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 3Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 4Health News:Singapore Offers Grants to Research Scientists to Start Labs Here 2Health News:Singapore Offers Grants to Research Scientists to Start Labs Here 3
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Double-ended. 4 mm x 10 mm flat edge like scraper and 2 mm x 11 mm semi sharp tip....
Designated most popular model or size. 3 mm tip....
Medicine Products: